Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2015

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aderhold V, Weinmann S, Hägele C, Heinz A (2014): Frontale Hirnvolumenminderung durch Antipsychotika? Nervenarzt 86: 302–323

    Article  Google Scholar 

  • Allroggen M, Udvardi PT, Pleuer PL, Kölch M, Fegert J M, Ludolph AG (2010): Langzeiteffekte von Psychostimulanzien - Welche Auswirkungen sind uns aus prä-/klinischen Studien bekannt. Psychopharmakotherapie 17: 125–131

    Google Scholar 

  • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601

    Google Scholar 

  • Anderson IM (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19–36

    Article  CAS  PubMed  Google Scholar 

  • Anonym (2013): Agomelatine: A review of its adverse effects. Prescrire Int 22: 70–71

    Google Scholar 

  • Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005): Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456

    Article  PubMed Central  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004a): Suizide und Suizidversuche unter Bupropion. Deutsches Ärzteblatt 101 : A 2139–2140

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004b) : SSRI und Suizidalität (Kurzfassung) Deut Ärztebl. 101 :A-2642 (Langfassung : www.aezteblatt.de/plus3904) Arzneimittelkommission der deutschen Ärzteschaft (2006): Hypersexualität unter Aripiprazol. Dtsch Ärztebl 103: A3518

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2008): Stellenwert von Antidepressiva in der Depressionsbehandlung. Arzneiverordnung in der Praxis 35: 42–43

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2009): Arzneiverordnungen. 22.

    Google Scholar 

  • Auflage, Medizinische Medien Informations GmbH (MMI), Neu-Isenburg Arzneimittelkommission der deutschen Ärzteschaft (2011): Aus der UAW-Datenbank: Abhängigkeitspotenzial unter Pregabalin (Lyrica®). Dtsch Ärztebl 108: A 183 Arzneimittelkommission der deutschen Ärzteschaft (2015a): Aus der UAW-Datenbank: Akutes Leberversagen unter Methylphenidat-Therapie. Dtsch Ärztebl 112: A 295–296

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2015b) Stellungnahme der AKdÄ zu Nalmefen (Selincro®) - frühe Nutzenbewertung §35a SGB V. News 2015–02

    Google Scholar 

  • Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010): Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71: 103–108

    Article  PubMed  Google Scholar 

  • Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014): Antipsychotika-Verordnungen bei Kindern und Jugendlichen: Auswertung von Daten einer gesetzlichen Krankenkasse für den Zeitraum 2005-2012. Dtsch Arztebl 111: 25–34

    Google Scholar 

  • Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H (2011): Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38: 270–273

    Article  PubMed  Google Scholar 

  • Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010):

    Google Scholar 

  • Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62: 36–42

    Google Scholar 

  • Bauer M, Grof P, Müller-Oerlinghausen B (Hsgb.) (2006): Lithium in Neuropsychiatry: The Comprehensive Guide. Informa healthcare. Oxon (UK)

    Book  Google Scholar 

  • Bschor T, Adli M (2009): Therapie depressiver Erkrankungen. Dtsch Ärztebl 105: A 782-A 792 Bschor T, Hartung HD (2008): Antidepressiva Kombinationsbehandlungen. In Bschor T (Hrsg): Behandlungsmanual therapieresistenter Depressionen. Kohlhammer, Stuttgart, S. 86–101

    Google Scholar 

  • Bschor T, Müller-Oerlinghausen B (2014): Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten Eine Entgegnung zur Presseerklärung der Deutschen Gesellschaft für Psychiatrie, Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Arzneiverordnung in der Praxis 41: Heft 2, 2–4

    Google Scholar 

  • Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C (2014): Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85: 1166–1170

    Article  CAS  PubMed  Google Scholar 

  • Bundesministerium für Gesundheit (2013): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach 38 § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Lixisenatid 5. September 2013, veröffentlicht am Mittwoch, 2. Oktober 2013, BAnz AT 02.10.2013 B–4

    Google Scholar 

  • Bundesministerium für Gesundheit (2015): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V): Lisdexamfetamindimesilat vom 14. November 2013, veröffentlicht am Donnerstag, 5. Dezember 2013 BAnz AT 05.12.2013 B–3

    Google Scholar 

  • Carlson GA, Potegal M, Margulies D, Basile J, Gutkovich Z (2010): Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar Disord 12: 205–212

    Article  PubMed Central  PubMed  Google Scholar 

  • Cipriani A, Koesters M, Furukawa TA, Nose M, Purgato M, Omori IM, Trespidi C, Barbui C (2012): Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012 Oct 17;10:CD00653–3

    Google Scholar 

  • Cipriani A, Hawton K, Stockton S, Geddes JR (2013): Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346: f3646,doi : 10.1136/bmj.f3646

    PubMed  Google Scholar 

  • Cipriani A, Rendell J, Geddes JR (2010): Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24: 1729–1738

    Article  CAS  PubMed  Google Scholar 

  • Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002): Recent trends in antipsychotic combina- tion therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75–84

    Article  PubMed  Google Scholar 

  • Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L (2013): European, randomized, phase 3 study of lisdexam- fetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23: 1208–1218

    Article  CAS  PubMed  Google Scholar 

  • Collins JC, McFarland BH (2008): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder .J Affect Disord 107: 23–28

    Article  CAS  PubMed  Google Scholar 

  • Connolly KR, Thase ME (2011): If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43–64

    Article  CAS  PubMed  Google Scholar 

  • Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (2011): ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365: 1896–1904

    Article  CAS  PubMed  Google Scholar 

  • Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011): Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343: d4551. doi: 10.1136/bmj.d4551

    Google Scholar 

  • Coyle CM, Laws KR (2015): The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacol 30: 152–163

    Article  CAS  Google Scholar 

  • Croissant B, Mann K (2004): Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30: 30–36

    Article  Google Scholar 

  • Dalsgaard S, 0stergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015): Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nation- wide cohort study. Lancet 385: 2190–2196

    Google Scholar 

  • Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009): Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675–682

    Article  PubMed  Google Scholar 

  • Dersch R, Zwernemann S, Voderholzer U (2011): Partial status epilepticus after electroconvul- sive therapy and medical treatment with bupropion. Pharmacopsychiatry 44: 344–346

    Article  CAS  PubMed  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2009): S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression. Internet: media.dgppn. de/mediadb/media/dgppn/pdf/leitlinien/s3-nvl-unipolare-depression-lf.pdf

    Google Scholar 

  • Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009): DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatrie 34: 50–51

    Google Scholar 

  • De Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012): The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 262: 79–86

    Article  PubMed  Google Scholar 

  • Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D (2013): Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase Illb study. CNS Drugs 27: 1081–1092

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Dolder CR, Nelson M, Snider M (2008): Agomelatine treatment of major depressive disorder. Ann Pharmacother 42: 1822–1831

    Article  CAS  PubMed  Google Scholar 

  • Food and Drug Administration (FDA) (2007): FDA proposes new warnings about suicidal think- ing, behaviour in young adults to take antidepressant medications. http://www.fda.gov/>bbs/topics/NEWS/2007/NEW01624.html

  • Fountoulakis KN, Möller HJ (2010): Efficacy of antidepressants: a re-analysis and re-interpreta- tion of the Kirsch data. Int J Neuropsychopharmacol 14: 405–412

    Article  PubMed  CAS  Google Scholar 

  • Friedmann PD (2013): Alcohol use in adults. N Engl J Med 368: 1655–1656

    Article  CAS  PubMed  Google Scholar 

  • Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000): The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15

    Article  CAS  PubMed  Google Scholar 

  • Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008): Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Int Med 149: 734–750

    Article  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library - Issue 1 Gemeinsamer Bundesausschuss (2010): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage III Nummer 44 Stimulantien vom 16. September 2010. Internet: www.g-ba.de/downloads/39-261-1185/2010-09-16_AM-RL3_Stimulantien_BAnz.pdf

  • Gentile S (2007): Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21: 367–387

    Article  CAS  PubMed  Google Scholar 

  • Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S (2014): Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 205: 44-51 3–8

    Google Scholar 

  • Gerhard T, Devanand DP, Huang C, Crystal S, Olfson M (2015) : Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Brit J Psychiatry 207: 46–51

    Article  Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators' suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363

    Article  PubMed  Google Scholar 

  • Goldberg TE, Gomar JJ (2009): Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166: 631–634

    Article  PubMed  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473

    Article  CAS  PubMed  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441

    Article  CAS  PubMed  Google Scholar 

  • Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009): Sudden death and use of stimulant medications in youths. Am J Psychiatry 166: 992100–1

    Article  Google Scholar 

  • Greil W, Häberle A, Haueis P, Grohmann R, Russmann S (2012): Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Affect Disord 136: 534–1542

    Article  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190

    Article  CAS  PubMed  Google Scholar 

  • Grof P (2013): Melancholia: a distinct entity? Can J Psychiatry 58: 181–182

    PubMed  Google Scholar 

  • Grof P, Müller-Oerlinghausen B (2009): A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 11 (Suppl 2): 10–19

    Article  CAS  PubMed  Google Scholar 

  • Grohmann R, Engel RR, Geissler KH, Rüther E (2004): Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmaco- psychiatry 37 Suppl 1: S27–38

    Google Scholar 

  • Grund T, Lehmann K, Bock N, Rothenberger A, Teuchert-Noodt G (2006): Influence of methylphenidate on brain development - an update of recent animal experiments. Behav Brain Funct 10: 2

    Article  CAS  Google Scholar 

  • Hägg S, Bate A, Stahl M, Spigset O (2008): Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31: 685–694

    Article  PubMed  Google Scholar 

  • Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008): Meta-analysis of major depressive disorder relapse and recurrence with second-genera- tion antidepressants. Psychiatr Serv 59: 1121–1130

    Article  PubMed Central  PubMed  Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79

    Article  PubMed  Google Scholar 

  • Healy D (2015): Serotonin and deprsssion. The marketing of a myth. BMJ doi:10.1136/bmj.h1771. (Published 21.4.2015)

    Google Scholar 

  • Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012): Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45: 114–118

    Article  CAS  PubMed  Google Scholar 

  • Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Reh- man F, Garg AX (2014): Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161: 242–248

    Article  PubMed  Google Scholar 

  • Janhsen K, Roser P, Hoffmann K (2015) : Probleme der Dauertherapie mit Benzodiazepinen und verwandten Substanzen. Dtsch Ärztebl 112: 1–7

    Google Scholar 

  • Jans T, Warnke A (2010): Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerk- samkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordnung in der Praxis. 37: 4–6

    Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006): The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163: 813–821

    Article  PubMed  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2010a): Wirkstoff Aktuell: Aripiprazol (Abilify ). Ausgabe 03/2010. Internet: http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Aripiprazol.pdf

  • Kassenärztliche Bundesvereinigung (2010b): Agomelatin. Wirkstoff aktuell, Ausgabe 05/2010 Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Agomelatin.pdf

  • Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009): Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in prima- ry care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii-iv, ix-xi, 1–159

    Google Scholar 

  • Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005): Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352: 2515–2523

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e4–5

    Article  Google Scholar 

  • Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010): Second-generation antipsy- chotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 Dec 8; (12): CD00814–1

    Google Scholar 

  • Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009): Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD00656–9

    Google Scholar 

  • Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S (2012): Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol 15: 449–457

    Article  CAS  PubMed  Google Scholar 

  • Kupfer DJ, Frank E, Phillips ML (2012): Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379: 1045-1055 3–8

    Google Scholar 

  • La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2014): Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46: 201–208

    Google Scholar 

  • Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (2011): Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 198: 341–345

    Article  PubMed  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a): How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429–447

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b): Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581–1589

    Article  CAS  PubMed  Google Scholar 

  • Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013): Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen Nervenarzt 84: 294–306

    Google Scholar 

  • Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015): The suicide protective effects of lithium:more than 20 years of evidence. Int. J Bipol Dis, i.Dr. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effec- tiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1233

    Google Scholar 

  • Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A (2015) : Efficacy and acceptability of pharmacological treatments for ndepressive disorders in primary care : a systematic review and network meta-analysis. Am Fam Med 13: 69–79

    Article  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software

    Google Scholar 

  • MacGorry P, Alvarez-Jimenez M, Killacker E (2013): Antipsychotic medication during the critical period following remission from first-episode psychosis:less is more. JAMA Psychiatry 7: 898–900

    Article  Google Scholar 

  • Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011): Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306: 1359–1369

    Article  CAS  PubMed  Google Scholar 

  • Maher AR, Theodore G (2012): Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18 (5 Suppl B): S1–20

    Google Scholar 

  • McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010): Drug Class Review: Atypical Anti- psychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science Univer- sity; July 2010. Internet: http://www.ncbi.nlm.nih.gov/books/NBK50583/

  • McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS (2014): Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311: 1978–1987

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610

    Article  PubMed  Google Scholar 

  • McGorry P, Alvarez-Jimenez M, Killackey E (2013): Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 70: 898–900

    Article  PubMed  Google Scholar 

  • McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012): Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728

    Article  CAS  PubMed  Google Scholar 

  • Meszaros A, Czobor P, Balint S, Komlosi S, Simon V, Bitter I (2009): Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychophar- macol 12: 1137–1147

    Google Scholar 

  • Miyamoto S, Miyake S, Jarskog LF, Fleischhacker WW, Lieberman JA (2012): Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206–1227

    Article  CAS  PubMed  Google Scholar 

  • Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Con- ners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040

    Article  PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65

    Article  PubMed  Google Scholar 

  • Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18

    Google Scholar 

  • Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157

    Article  PubMed Central  PubMed  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086

    Article  Google Scholar 

  • Müller-Oerlinghausen B (2011): Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordnung in der Praxis 39: 60–62

    Google Scholar 

  • Müller-Oerlinghausen B (2012): Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra. Nervenarzt 83: 1191–1192

    Article  PubMed  Google Scholar 

  • Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013): Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82: 132–141

    Article  PubMed  Google Scholar 

  • Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, For The Cafe Investigators (2009): Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111: 9–16

    Article  PubMed  Google Scholar 

  • Pottgard A, Hallas J, Jensen BL, Madsen K, Friis S (2015): Longterm lithium-use and risk of renal and upper urinary tract cancers. JASN. Doi:10.1681/ASN,2015010061

    Google Scholar 

  • Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcom- mittee of American College of Physicians (2008): Using second-generation antidepres- sants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149: 725–733

    Article  PubMed  Google Scholar 

  • Rani F, Murray ML, Byrne PJ, Wong IC (2008): Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121: 1002–1009

    Article  PubMed  Google Scholar 

  • Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Reeves RR, Ladner ME (2010): Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16: 227–234

    PubMed  Google Scholar 

  • Remschmidt H, Global ADHD Working Group (2005): Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14: 127–137

    Article  Google Scholar 

  • Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group (2010): Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136–145

    Article  PubMed Central  PubMed  Google Scholar 

  • Rösner S, Leucht S, Lehert P, Soyka M (2008): Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22: 11–23

    Article  PubMed  Google Scholar 

  • Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: http://>guidance.nice.org.uk/CG1/guidance/pdf/>English

    Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680

    Article  CAS  PubMed  Google Scholar 

  • Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012): Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21: 2070–2078

    Article  PubMed Central  PubMed  Google Scholar 

  • Schubert I, Köster I, Lehmkuhl G (2010): Prävalenzentwicklung von hyperkinetischen Störungen und Methylphenidatverordnungen: Analyse der Versichertenstichprobe AOK Hessen/>KV Hessen zwischen 2000 und 2007. Dtsch Arztebl Int 107: 615–621

    PubMed Central  PubMed  Google Scholar 

  • Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011): A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123: 247–265

    Article  CAS  PubMed  Google Scholar 

  • Shine B, McKnight RF, Geddes JR (2015): Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015 May 20 [Epub ahead of print]

    Google Scholar 

  • Siegmund-Schulze N (2012): Polypharmakotherapie im Alter: Weniger Medikamente sind oft mehr. Dtsch Ärztebl 109: A418–A420

    Google Scholar 

  • Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Be- doya D, Anderson R, Hamer RM, Lieberman JA (2008): Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165: 1420–1431

    Article  PubMed  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepres- sants: a meta-analysis. Br J Psychiatry 180: 396–404

    Article  PubMed  Google Scholar 

  • Smith EG, Austin L, Kim HM, Eisen SV, Kilbourne AM, Miller DR, K, Hannemann C, Sauer BC, Valenstein M (2015) : Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Brit J Psychiatry 207: 55–63

    Article  Google Scholar 

  • Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P (2012): A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45: 100–107

    Article  CAS  PubMed  Google Scholar 

  • Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16

    Article  PubMed  Google Scholar 

  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013): Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10(3): e1001403 Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012): Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73: 812–820

    Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25: 137–153

    PubMed Central  CAS  PubMed  Google Scholar 

  • Stübner S, Grohmann R, von Strahlendorff I, Rüther E, Möller HJ, Müller-Oerlinghausen B, Engel R, Horvarth A, Greil W (2010): Suicidality as a rare advserse event of antidepressant medi- cation. Report from the AMSP Multicenter Drug Surveillance Project. J Clin Psychiatry 71: 1293–1307

    Article  PubMed  Google Scholar 

  • Svensson S, Mansfield PR (2004): Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73: 10–16

    Article  PubMed  Google Scholar 

  • Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006): Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45: 1304–1313

    Article  PubMed  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26

    Article  CAS  PubMed  Google Scholar 

  • Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008): Benefits and risks of antipsychotic polyp- harmacy: an evidence-based review of the Literature. Drug Saf 31: 7–20

    Article  CAS  PubMed  Google Scholar 

  • Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011): Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific Literature. PLoS Med 8: e1000434 Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012): The ad- verse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2 7: 156–169

    Google Scholar 

  • Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008): Selective publication of antidepressant triuals and its influence on apparent efficacy. N Engl J Med 358: 252–260

    Article  CAS  PubMed  Google Scholar 

  • Ujeyl M, Müller-Oerlinghausen B (2012): Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Ãœbersicht. Schmerz 26: 523–536

    Article  CAS  PubMed  Google Scholar 

  • Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009): Antipsycho- tics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19: 629–635

    Article  CAS  PubMed  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217

    Article  CAS  PubMed  Google Scholar 

  • Wagstaff AJ, Ormrod D, Spencer CM (2001): Tianeptine: a review of its use in depressive disorders. CNS Drugs 15: 231–259

    Article  CAS  PubMed  Google Scholar 

  • Walder A, Greil W, Baumann P (2009): Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33: 1286–1287

    Article  CAS  PubMed  Google Scholar 

  • Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW (2012): Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig 32: 497–512

    Article  CAS  PubMed  Google Scholar 

  • Weinmann S, Read J, Aderhold V (2009): Influence of antipsychotics on mortality in schizo- phrenia: systematic review. Schizophr Res 113: 1–11

    Article  PubMed  Google Scholar 

  • Wensel TM, Powe KW, Cates ME (2012): Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46: 424–429

    Article  PubMed  CAS  Google Scholar 

  • Whitaker R (2010): Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonish- ing rise of mental illness in America. Crown Publishing, New York Wolter DK (2009): Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Ãœbersicht. Z Gerontopsychol psychiatr 22: 17–56

    Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 18: 262–276

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Lohse, M., Müller-Oerlinghausen, B. (2015). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_38

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_38

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation